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Background: Cardiac magnetic resonance (CMR) has been shown to improve the
diagnosis of myocarditis, but no systematic comparison of this technique is currently
available. The purpose of this study was to compare the 2009 and 2018 Lake Louise
Criteria (LLC) for the diagnosis of acute myocarditis using 3.0 T MRI with endomyocardial
biopsy (EMB) as a reference and to provide the cutoff values for multiparametric
CMR techniques.
Methods: A total of 73 patients (32 ± 14 years, 71.2% men) with clinically suspected
myocarditis undergoing EMB and CMR with 3.0 T were enrolled in the study. Patients
were divided into two groups according to EMB results (EMB-positive and -negative
groups). The CMR protocol consisted of cine-SSFP, T2 STIR, T2 mapping, early and late
gadolinium enhancement (EGE, LGE), and pre- and post-contrast T1 mapping. Their
potential diagnostic ability was assessed with receiver operating characteristic curves.
Results: The myocardial T1 and T2 relaxation times were significantly higher in
the EMB-positive group than in the EMB-negative group. Optimal cutoff values
were 1,228ms for T1 relaxation times and 58.5ms for T2 relaxation times with
sensitivities of 86.0 and 83.7% and specificities of 93.3 and 93.3%, respectively.
The 2018 LLC had a better diagnostic performance than the 2009 LLC in terms
of sensitivity, specificity, positive predictive value, and negative predictive value. T1
mapping + T2 mapping had the largest area under the curve (0.95) compared to
other single or combined parameters (2018 LLC: 0.91; 2009 LLC: 0.76; T2 ratio:
0.71; EGEr: 0.67; LGE: 0.73; ). The diagnostic accuracy for the 2018 LLC was
the highest (91.8%), followed by T1 mapping (89.0%) and T2 mapping (87.7%).
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Conclusion: Emerging technologies such as T1/ T2 mapping have significantly
improved the diagnostic performance of CMR for the diagnosis of acute myocarditis.
The 2018 LLC provided the overall best diagnostic performance in acute myocarditis
compared to other single standard CMR parameters or combined parameters. There
was no significant gain when 2018LLC is combined with the EGE sequence.
Keywords: myocarditis, cardiovascular magnetic resonance (CMR), diagnostic performance, Lake Louise criteria,
endomyocardial biopsy
INTRODUCTION
Myocarditis is an inflammatory myocardial disease that is
characterized by myocyte necrosis and inflammatory cell
infiltrates (1). It is an important cause of cardiac morbidity and
mortality that accounts for up to 20% of deaths in adults younger
than 40 years (2). About 25% of patients withmyocarditis develop
persistent cardiac dysfunction, and 12–25% of the patients will
rapidly deteriorate or die or progress to dilated cardiomyopathy
(3). To timely treat patients, early and correct diagnosis is of
the highest importance for patients with myocarditis. However,
the diagnosis of myocarditis is challenging due to its diverse
etiology and heterogeneous clinical manifestations, going from
asymptomatic or subclinical to severe heart failure, arrhythmia,
and death.
At present, endomyocardial biopsy (EMB) remains the gold
standard for diagnosis of myocarditis (1). However, EMB is
an invasive examination, the recommended indications are
confined to limited clinical situations, such as life-threatening
arrhythmia patients. Cardiac magnetic resonance (CMR) is a
noninvasive tool that can characterize myocardial changes for
diagnosis of myocarditis (4, 5). In 2009, consensus criteria for
CMR in myocardial inflammation known as the Lake Louise
Criteria (LLC) were established (6). The myocarditis diagnosis is
based on conventional MRI techniques, including T2-weighted
imaging (T2WI), early gadolinium enhancement (EGE), and
late gadolinium enhancement (LGE), which refer to myocardial
edema, hyperemia, and fibrosis, respectively. However, these are
qualitative and semi-quantitative diagnostic criteria that mainly
depend on visual assessment or signal intensities of a reference
tissue sample. For LGE analysis, areas of hyperenhancement
were assessed visually. Subtle and diffuse fibrosis were easy to
be missed by LGE, as there is no area of normal myocardium
with which to compare signal intensity (7). Novel quantitative
technology of myocardial T1/T2 mapping can directly measure
the T1 and T2 values of myocardial tissue without normal
myocardium as a reference. More and more studies have
demonstrated the feasibility of mapping technology in the
diagnosis of myocarditis (4, 8). Therefore, the LLC were revised
in 2018 to recommend that at least one T1-based criterion (T1
mapping, ECV, and LGE) and at least one T2-based criterion
(T2WI and T2 mapping) should be used (9). To date, some
studies have focused on the diagnostic performance of LLC,
but their sample size was relatively small, and they did not
use EMB as the gold standard for the diagnosis of myocarditis
(10–12). Most of the studies were performed on 1.5T scanner
systems, and no comprehensive data for CMR imaging using
3.0 T in patients with acute myocarditis exist so far (11, 13, 14).
The study by Luetkens et al. published in 2014 provided the
results for a 3.0 T scanner (4), but the diagnostic performance
of T2 mapping and the 2018 LLC were not studied. In 2019, the
2018 LLC were added to their investigation (12), but the study
mainly validated previously reported cutoff values for parametric
mapping techniques and the diagnostic efficiency of different
sequences combination was not evaluated. Radunski et al. studied
only one combined parameter (LGE+ ECV) and did not further
analyze any others (14).
The purpose of the present study was to compare the 2009
LLC and the 2018 LLC for the diagnosis of acute myocarditis
using 3.0 T MRI with EMB as a reference, further analyzed the
diagnostic efficiency of different sequence combinations, and
provide the cutoff values for multiparametric CMR techniques.
METHODS
Subjects
The study was approved by the Research Ethics Committee of
the Fuwai Hospital, Beijing, China (approval number: 2020-
1274), and all subjects provided written informed consent.
Consecutive patients with clinically suspected myocarditis who
underwent gadolinium-enhanced CMR and EMB at Fuwai
Hospital between January 2016 and December 2020 were
enrolled in this study. Myocarditis was suspected in patients
who fulfilled the following criteria as recommended by the
European Society of Cardiology Working Group on myocardial
and pericardial diseases (1): (1) clinical presentations suggestive
of myocarditis (acute chest pain, dyspnea at rest or exercise,
palpitation, or fatigue); (2) evidence of myocardial damage
(functional and structural abnormalities, newly abnormal 12-
lead ECG or elevated TnT/TnI). Exclusion criteria included
contraindications to CMR, evidence of myocardial infarction,
and other cardiac diseases. Patients with infarct patterns of LGE
on CMR were also excluded. Cardiac MRI did not influence
the diagnostic algorithm. Whether to do biopsy and CMR is
decided by the physician according to the patient’s condition.
As a radiologist, we did not intervene in any examination and
treatment of patients. If the physician thinks that the patient
needs CMR, we will ask for the patient’s consent and scan
according to our CMR scanning protocol. Clinical data such as
time intervals between the onset of symptoms to cardiacMRI and
results of laboratory examination were also collected.
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FIGURE 1 | CMR and pathology results for a representative case of myocarditis. (A) T2 STIR, (B) EGE, (C) LGE, (D) native T1, (E) ECV, and (F) T2 mapping.
hematoxylin-eosin(HE) staining (×10) (G) indicates focal myocyte damage with lymphocytic infiltration. Immunohistochemistry revealed (H) LCA + (×40) and (I) CD20
+ (×40).
CMR Protocols and Image Analysis
Gadolinium-enhanced CMR imaging was performed on a 3.0T
scanner (Ingenia; Philips Healthcare, Best, the Netherlands).
The balanced steady-state free precession cine images were
obtained using short-axis slices from the atrioventricular ring
to the left ventricular (LV) apex and two- and four-chamber
views with the following parameters: slice thickness: 8mm,
gap: 2mm, TR: 2.9–3.4ms, TE: 1.5–1.7ms, matrix size: 192
× 224–224 × 256, and FOV: 320–380mm. T2-weighted short
tau inversion recovery (T2 STIR) sequences were performed
in three LV short-axis (basal, mid, and apical) and four-
chamber views (TR: 2 R–R intervals, TE: 80ms, FOV: 300–
380mm, matrix: 160 × 143, and voxel size: 2.0 × 2.0 × 8mm).
For T1 mapping, a modified Look-Locker inversion recovery
(MOLLI) sequence was used for T1 quantification, which was
acquired in three LV short-axis views (basal, mid, and apical
ventricular short-axis planes). MOLLI images were acquired
before intravenous gadolinium administration as well as 15min
after administration of gadolinium (0.2 mmol/kg, gadopentetate
dimeglumine, Magnevist R©, Bayer Healthcare Pharmaceuticals,
Wayne, NJ, USA). The pre-contrast MOLLI acquisition followed
the 5(3)3 protocol during a breath-hold. Post-contrast MOLLI
images followed the 4(1)3(1)2 protocol during a breath-hold.
For myocardial T2 mapping, a six-echo gradient spin-echo
(GraSE) sequence was used as previously described in the
short-axis through basal, mid-ventricular, and apical planes
(15). Blood hematocrit levels were determined on the day of
examination. EGE was assessed 3min after intravenous injection
of extracellular contrast agent in three LV short-axis views. A
spoiled gradient turbo fast low-angle shot sequence with phase
sensitive inversion recovery (PSIR) was used for the LGE images,
which were acquired 10min after administration of gadolinium
contrast agent using the four-chamber view, two-chamber view,
and a series of contiguous 6-mm LV short-axis slices covering the
entire LV. Figure 1 shows the CMR and pathology results of a
representative case.
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All CMR images were transferred to an offline workstation
with commercial post-processing software QMass (Medis R©
QMass, Leiden, the Netherlands) for blinded analysis. Cardiac
MRI analysis was performed by a radiologist (S.L. with 4 years
of CMR experience) who was blinded to the patients’ clinical
data and EMB results. The dimensions of the cardiac chambers
(left atrium dimension, LAD, LV end-diastolic diameter, and
LVEDD), LV volumes (LV end-diastolic volume, LVEDV, LV
end-systole volume, and LVESV), and LVEF were measured
using standard volumetric techniques (16). LVEDV and LVESV
were adjusted for body surface area (BSA) and expressed as
indexes. T2 STIR and LGE images were assessed visually and
considered positive when a typical pattern of myocarditis was
present (6). Semiquantitative T2 signal intensity ratio and EGE
ratio were calculated using the signal intensity ratio of the
myocardium and the skeletal muscle as recommended (9). LV
endocardial and epicardial borders were drawn manually to
define the myocardium. Myocardial T1 and T2 values were
measured on the basal, mid, and apical short-axis slices according
to the American Heart Association 17-segment model (apex
excluded), and the global T1 and T2 relaxation times were
calculated. Previously described methods were used to calculate
the myocardial extracellular volume (ECV) fraction from the T1
map measurements, yielding global ECV fraction values (17, 18).
Inter- and intra-observer variability for T1 and T2 values of
the LV segments were assessed in 20 randomly selected subjects,
such that one observer performed one measurement, and a
second observer blinded to the first observer’s results measured
two time points at least 1 week apart.
Endomyocardial Biopsy
EMB was performed with standard techniques as previously
described (19). At least three bioptic samples, each 1–2mm in
size, were obtained from the right ventricle in each patient and
immediately fixed in 10% buffered formalin at room temperature
for light microscopic examination. The principal antibodies used
for immunophenotype characterization were CD3, CD20, CD4,
CD8, and CD68.
Statistical Analysis
Statistical analysis was performed using the SPSS 23.0 software.
Values are expressed as the mean ± SD or as a percentage,
as appropriate. Univariate comparisons were performed
using Student’s t-test, the Mann–Whitney U-test, and Fisher’s
exact test for normally distributed, non-normally distributed,
and categorical variables, respectively. A receiver operating
characteristic (ROC) analysis was performed to calculate areas
under the curve. The optimal cutoff point was identified using
the Youden index, which is the maximum of (sensitivity +
specificity-1). Diagnostic accuracy, sensitivities, specificities,
accuracies, positive predictive values (PPV), and negative
predictive values (NPV) were also calculated. Differences
between sensitivities and specificities were calculated with
McNemar’s test. For the evaluation of intra- and inter-observer
variability, the intra-class correlation coefficient was used.
Results were considered significant if p < 0.05.
RESULTS
Population
A total of 73 subjects [aged 32 ± 14 years (14–68 years), 52
males] were enrolled in the present study, 43 of whom were
confirmed to have myocarditis by EMB (EMB-positive group).
Among 43 patients with EMB confirmed myocarditis, there
were 38 lymphocytic myocarditis, three giant cell myocarditis
and two eosinophilic myocarditis. Three patients had no
immunohistochemical results. Of the remaining 40 patients, 40
patients were CD3 positive, 40 patients were CD4 positive, 39
patients were CD8 positive, 15 patients were CD20 positive, 27
patients were CD68 positive. Of the remaining 30 EMB-negative
patients, 18 patients were presenting with arrhythmia, six with
dilated cardiomyopathy, one with paraganglioma (bladder), three
with pericardial effusion, one with hyperuricosuria, and one with
coronary artery anomaly. Most of the patients presenting with
arrhythmia were idiopathic, including ventricular tachycardia,
sinus bradycardia, ventricular premature contraction and left
or right bundle branch block. Only one patient could not be
excluded from having arrhythmogenic cardiomyopathy. There
were no statistically significant differences in gender or age
between the EMB-positive and -negative groups (33 ± 13 years
vs. 30 ± 16 years, p = 0.50; 67.4 vs.76.7%, p = 0.44). The C-
reactive protein levels and white blood cell in the EMB-positive
group were higher than those in the EMB-negative group (both
p < 0.05). Thirty-two out of 43 patients in the EMB-positive
group had abnormal ECG: three had ventricular fibrillation, 14
had ventricular tachycardia, six had ST-T abnormalities, four
had atrioventricular block or bundle branch block, three had
sinus arrhythmia, and two had atrial fibrillation. There was
no significant difference in time intervals between onset of
symptoms to cardiac MRI between the two groups (p = 0.93).
The baseline characteristics of the study population are detailed
in Table 1.
Diagnostic Performance of Single CMR
Parameters
All CMR findings for the two groups are shown in Table 2.
There was no significant difference between the two groups in
the dimension of the cardiac chambers (LAD: 30.7 ± 10.4mm
vs. 27.7 ± 8.0mm, p = 0.17; LVEDD: 53.8 ± 10.0mm vs. 50.9
± 8.0mm, p = 0.17) and cardiac function (48.7 ± 16.9% vs.
50.4 ± 12.3%, p = 0.62). T2-ratio (2.3 ± 0.4 vs. 1.7 ± 0.3; p
= 0.003) and EGEr (4.0 ± 1.0 vs. 3.3 ± 1.2; p = 0.014) were
significantly higher in the EMB-positive group than in the EMB-
negative group. Of the 73 patients, 42 patients (57.5%) had non-
ischemic LGE, including 33 patients (76.7%) in the EMB-positive
group and nine patients (30.0%) in the EMB-negative group.
The myocardial T1 and T2 relaxation times were significantly
prolonged in the EMB-positive group compared to the EMB-
negative group (1,252± 42ms vs. 1,195± 43ms, p < 0.001; 63.2
± 6.1ms vs. 54.5± 3.7ms, p < 0.001).
For the diagnostic efficiency of a single CMR parameter,
ROC curves showed that T1 mapping and T2 mapping have the
largest area under the curve (AUC) of 0.90 compared to other
single CMR parameters (Figure 2A). Optimal cutoff values were
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Age (y) 32 ± 14 33 ± 13 30 ± 16 0.500
Male (n) 52 (71.2%) 29 (67.4%) 23 (76.7%) 0.441
BSA (m2) 1.78 ± 0.20 1.76 ± 0.19 1.82 ± 0.20 0.259
Heart rate
(beats/min)
72 ± 15 75 ± 16 69 ± 12 0.080
HCT (%) 42.0 ± 5.5 42.1 ± 5.1 41.9 ± 6.0 0.870
cTnI (ng/ml) 7.7 ± 7.9 11.3 ± 7.0 1.8 ± 9.4 0.001
WBC (103/µL) 8.3 ± 4.3 9.2 ± 4.9 6.9 ± 3.5 0.019





10 ± 8 10 ± 8 10 ± 8 0.925
ECG
abnormalities (n)
54 (74.0%) 32 (74.4%) 22 (73.3%) 0.917
BSA, body surface area; HCT, hematocrit; WBC, white blood cell; CRP, C-reactive protein.
TABLE 2 | CMR characteristics in EMB-positive and EMB-negative groups.
EMB positive (n = 43) EMB negative(n = 30) p
LAD (mm) 30.7 ± 10.4 27.7 ± 8.0 0.166
LVEDD (mm) 53.8 ± 10.0 50.9 ± 8.0 0.172
LVEF (%) 48.7 ± 16.9 50.4 ± 12.3 0.624
EDVi (mL/m2) 95.1 ± 35.3 83.9 ± 29.8 0.150
ESVi (mL/m2 ) 52.3 ± 35.8 43.9 ± 27.2 0.259
T2 ratio 2.3 ± 0.4 1.7 ± 0.3 0.003
EGE ratio 4.0 ± 1.0 3.3 ± 1.2 0.014
LGE 33 (76.7%) 9 (30.0%) <0.001
Native T1 (ms) 1,252 ± 42 1,195 ± 43 <0.001
ECV (%) 32.7 ± 3.3 29.3 ± 4.1 <0.001
T2 (ms) 63.2 ± 6.1 54.5 ± 3.7 <0.001
2009LLC 34 (79.1%) 8 (26.7%) <0.001
2018LLC 41 (95.3%) 4 (13.3%) <0.001
LAD, left atrium dimension; LVEDD, left ventricular end diastolic diameter; EDVi, index
value for left ventricular end-diastolic volume; ESVi, index value for left ventricle end-systole
volume; EGE, early gadolinium enhancement ratio; LGE, late gadolinium enhancement;
ECV, extracellular volume fraction; LLC, Lake Louise criteria.
1,228ms for T1 relaxation times and 58.5ms for T2 relaxation
times, with sensitivities of 86.0 and 83.7%, specificities of 93.3 and
93.3%, positive predictive values of 94.9 and 94.7%, and negative
predictive values of 82.4 and 80.0%, respectively. The AUC of
EGEr was the smallest (0.76), followed by the T2 ratio (0.71)
and LGE (0.73). The diagnostic performance of ECV (AUC-0.78)
was second only to T1 and T2 mapping, but it had the lowest
sensitivity (65.1%) among all single parameters with a cutoff
value of 31.0%. The T2 ratio sensitivity was lower than that of
the T2 relaxation times (69.8 vs. 83.7%, p = 0.039), although the
differences in specificity between the T2 ratio and T2 relaxation
times were not statistically significant (80.0 vs. 93.3%, p= 0.109).
Diagnostic performance and cutoff values for all cardiac MR
parameters are provided in Table 3.
Diagnostic Performance of LLC and
Combined CMR Parameters
ROC curves showed that the 2018 LLC yielded a higher AUC
than the 2009 LLC (0.91 vs. 0.76) with a sensitivity of 95.3%
and specificity of 86.7% (Figure 2B). Although the sensitivity and
specificity of the 2009 LLC were lower than those of the 2018
LLC, the difference in specificity was not statistically significant
(sensitivity: 79.1 vs. 95.3%, p= 0.008; specificity: 73.3 vs. 86.7%, p
= 0.125). All patients diagnosed with myocarditis using the 2009
LLC were correctly identified by the 2018 LLC, although seven
patients were missed by the 2009 LLC. Of the 30 patients who
had no evidence of myocarditis in the EMB tests, eight patients
(26.7%) were diagnosed with myocarditis by 2009 LLC criteria,
and four patients (13.3%) were diagnosed with myocarditis by
2018 LLC criteria. The relationships between the 2009 and 2018
LLC with EMB results are shown in Figure 3.
For the diagnostic performance of combined CMR
parameters, the combination of native T1 and T2 mapping
showed the best AUC (0.95) among all combined parameters and
LLC. When the T2 ratio was combined with LGE, the area under
the curve was the smallest (0.76). Although the AUC of T2 ratio
+ LGE was very similar to 2009 LLC, its diagnostic accuracy
was lower (71.2 vs. 76.7%; Figure 4). When the 2018LLC was
combined with EGEr, the AUC of 2018LLC + EGEr has little
change compared with 2018LLC, but the diagnostic accuracy was
significantly reduced (79.5 vs. 91.8%). The combination of LGE
and T2 mapping had a higher diagnostic accuracy (79.5%) than
the T2 ratio+ LGE (71.2%) and a lower diagnostic accuracy than
the T1 mapping+ T2 mapping (82.2%).
Intra- and Inter-observer Variability
The intra-class correlation coefficient (ICC) values for inter-
and intra-observer variability for T1 relaxation times were 0.96
and 0.97, respectively. The ICC values for inter- and intra-
observer variability for T2 relaxation times were 0.95 and
0.96, respectively.
DISCUSSION
To the best of our knowledge, this is the first study to compare
the diagnostic performance between the original 2009 LLC and
the updated 2018 LLC with EMB as a reference using 3.0T
in a relatively large patient population, further analyzed the
diagnostic efficiency of different sequence combinations, and
provide the cutoff values for multiparametric CMR techniques.
We found that: (1) the 2018 LLC had a better diagnostic
performance than the 2009 LLC with respect to sensitivity,
specificity, PPV, and NPV, with a cutoff value of 1,228ms for
native T1, 58.5ms for T2 relaxation times, and 31.0% for ECV;
(2) when the 2018 LLC and EGEr were combined, the diagnostic
accuracy and precision did not increase compared to the 2018
LLC; and (3) mapping technology significantly improved the
diagnostic efficiency. Areas under the curve for T1 mapping +
T2 mapping were higher compared to those of other cardiac MR
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FIGURE 2 | ROC curves for diagnostic performance of CMR parameters and LLC. (A) T2 signal intensity (SI) ratio (AUC, 0.71), early gadolinium enhancement ratio
(EGEr) (AUC, 0.67), late gadolinium enhancement (LGE) (AUC, 0.73), T1 mapping (AUC, 0.90), extracellular volume (ECV) (AUC, 0.78), and T2 (AUC, 0.90). (B) 2009
Lake Louise Criteria (LLC) (AUC, 0.76), 2018 LLC (AUC, 0.91), T2 ratio + LGE (AUC, 0.76), T1 mapping + T2 mapping (AUC, 0.95), 2018 LLC + EGEr (AUC, 0.91),
and LGE + T2 mapping (AUC, 0.91).
TABLE 3 | Diagnostic performance of different cardiac MRI parameters for diagnosis of acute myocarditis.
Cut off Sensitivity (%) Specificity (%) PPV (%) NPV (%) LR+ LR- DOR
T2 ratio 1.9 69.8 80.0 83.3 64.9 3.5 0.4 8.8
EGEr 3.8 72.1 50.0 67.4 55.6 1.4 0.6 2.3
LGE – 76.7 70.0 78.6 67.7 2.6 0.3 8.7
Native T1 (ms) 1,228 86.0 93.3 94.9 82.4 12.8 0.2 64.0
ECV (%) 31.0 65.1 83.3 84.8 62.5 3.9 0.4 9.8
T2 (ms) 58.5 83.7 93.3 94.7 80.0 12.5 0.2 62.5
2009LLC – 79.1 73.3 80.9 71.0 3.0 0.3 10.0
2018LLC – 95.3 86.7 91.1 92.9 7.2 0.1 72.0
EGE, early gadolinium enhancement ratio; LGE, late gadolinium enhancement; ECV, extracellular volume fraction; LLC, Lake Louise criteria; PPV, positive predictive value; NPV, negative
predictive value; LR+, positive likelihood ratio; LR-, negative likelihood ratio; DOR, diagnostic odds ratio.
parameters, which is a positive sign for patients who cannot use
contrast agents. However, mapping technology is influenced by
the field strength and acquisition techniques, thus the reliability
of the results still needs to be further evaluated.
T2WI
Inflammation causes myocardial cell edema, which alters
myocardial T2 relaxation time and therefore appears
hyperintense on T2WI. Triple inversion recovery turbo
spin echo sequences with inversion pulses provide excellent
contrast between edema and normal myocardium, improving
the detection of myocardial edema (20). But at the same time,
the T2WI image quality is affected by many factors, such as
sequence parameters, patient’s breathing, and arrhythmia.
Patients with slow intracardiac blood flow may exhibit an
increase in subendocardial blood flow signal, which is easy to
misdiagnose (21). This may be the reason why the sensitivity of
T2WI in this study was slightly lower (69.8%). The diagnostic
accuracy of T2WI was 73.9% in the present study, which was
higher than that in the Luetkens et al. study (68%) (4). The cutoff
value for the T2 ratio was 2.09 in their study, which was a little
higher than the value in the current study (T2 ratio: 1.9).
EGE
Tissue inflammation causes regional vasodilation, and the
increased blood volume in the inflammatory area leads to an
increased uptake of contrast agents during the early washout
period (6). Therefore, we can assess myocardial hyperemia by
calculating the EGEr. However, it had the lowest AUC for
diagnosing myocarditis among all of the parameters (0.67), with
a specificity of 50.0%. Therefore, it was removed from the LLC
in 2018 (9). The present ROC curves showed that the diagnostic
precision of T2 ratio + LGE was very similar to that of the
2009 LLC after removing the EGEr from the 2009 LLC. Both of
them had an AUC of 0.76. However, the diagnostic accuracy of
T2 ratio + LGE was lower than that of the 2009 LLC (71.2 vs.
76.7%). Chu et al. also found that removing the EGE from the
2009 LLC does not significantly reduce diagnostic accuracy for
myocarditis, although the positive likelihood ratiomay be slightly
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FIGURE 3 | Relationships between 2009 and 2018 LLC with EMB. Eight out of 30 (26.7%) patients without evidence of myocarditis in EMB tests were diagnosed
with myocarditis according to the 2009 LLC. All patients diagnosed with myocarditis by the 2009 LLC were correctly identified by the 2018 LLC, but seven patients
were missed by the 2009 LLC.
lower (22). Nevertheless, many experts still recommend using
EGE by providers with sufficient experience, as it reflects the
tissue changes of the myocardium-hyperemia and capillary leak.
LGE
Fibrosis caused by severe inflammation can be detected using
LGE imaging. Most LGEs occur in the sub-epicardium or mid-
myocardium and are more common in the inferolateral and
anteroseptal segments, which is very helpful for the diagnosis and
differential diagnosis (23). Some studies have shown that LGE
has high specificity (80–100%), but poor sensitivity (35–59%) and
accuracy (49–71%) (11, 14, 24). The specificity was even lower
in our study (70%). This may be because the EMB was used as
the gold standard, and the false-negative rate of EMB is high. In
our study, nine patients showed a typical LGE enhancement, but
there was no evidence of inflammation in the EMB results.
Mapping/ECV
T1 and T2 relaxation times are obtained on a pixel-by-pixel basis
and displayed as maps (9). These novel quantitative techniques
can overcome the limitations of conventional LGE in order to
assess the diffuse myocardial injury. In the present study, native
T1 yielded an excellent diagnostic performance with a sensitivity
of 86.0% and a specificity of 93.3%, which is similar to a study
by Luetkens et al. (13). At present, the cut-off values for T1
relaxation times are mainly obtained using the 1.5T ranges from
852 to 1,074ms (4, 13, 25). The cut-off value for T1 mapping
was 1,228ms in the present study. However, there is considerable
variability in T1 relaxation times between different field strengths
and different acquisition techniques. Therefore, each medical
center needs to establish its own normal range for native T1.
T2 mapping can detect myocardial water content by quantifying
the myocardial tissue T2 relaxation time. Compared to T2WI, T2
mapping wasmore sensitive tomyocardial edema. The sensitivity
of T2 mapping was significantly higher than that of the T2 ratio
(83.7 vs. 69.8%).
ECV is obtained using T1 maps acquired pre- and post-
administration of gadolinium-based contrast agent and adjusted
for the hematocrit value. The present study found that ECV had
no significant advantage over T1 mapping in the diagnosis of
acute myocarditis. It had an AUC of 0.78 with a cutoff value
of 31.0%. Our results were similar to those of Luetkens et al.
(4). ECV had a sensitivity of 67% and a specificity of 81% in
their study. However, a recent study showed that ECV is an
independent predictor of adverse cardiovascular events and that
T1mapping could not predict adverse cardiovascular events (26).
Lake Louise Criteria
The diagnostic performance of the 2018 LLC is better than that
of the 2009 LLC in terms of sensitivity, specificity, PPV, and
NPV. However, when the 2018 LLC and EGEr were combined,
the diagnostic accuracy and precision did not increase compared
to the 2018 LLC. The specificity and NPV were significantly
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FIGURE 4 | Diagnostic accuracies for CMR parameters and Lake Louise criteria. EGEr, early gadolinium enhancement ratio; LGE, late gadolinium enhancement; ECV,
extracellular volume fraction; LLC, Lake Louise criteria.
decreased by EGEr. Although T1 and T2 relaxation times had the
best diagnostic performance for T1WI and T2WI, respectively,
the diagnostic accuracy of T1 mapping + T2 mapping was lower
than that of the 2018 LLC. The combination of T1 mapping and
T2 mapping is a highly attractive option because this protocol is
gadolinium-free, which is very useful for patients who cannot use
contrast agents.
Although cardiovascular magnetic resonance imaging
provides non-invasive tissue characterization of the myocardium
and can support the diagnosis of myocarditis, it has little value in
identification of infiltrate type, and an attempt to establish cause.
Limitations
The present study had some limitations. First, this is a single-
center study with a relatively small sample size. Second, although
EMB was used as the gold standard for diagnosis, it can lead to
false-negative results due to sampling errors. Some patients with
myocarditis may be included in the EMB negative group. This
leads to a decrease in specificity and negative predictive value.
Furthermore, EMB was only performed in those subjects with
unexplained heart failure and/or new onset arrhythmias which
resulted in selection bias. However, the clinical diagnosis is not
equal to the real diagnosis of patients, because the specificity
of 2013ESC diagnostic criteria is low (27). Third, the dose of
contrast agent used in this study is slightly higher. In addition,
the results of CMR may have a certain impact on biopsy, but will
not cause a great deal of error/bias. As 21(28.8%) of the patients
had biopsy before CMR, including 15 CMR positive patients and
6 CMR negative patients in our study cohort.
CONCLUSIONS
The 2018 LLC provided the best overall diagnostic performance
in acute myocarditis compared to other single standard CMR
parameters or combined parameters. There was no significant
gain when 2018LLC is combinedwith the EGE sequence. Looking
for a better combination of CMR sequences and improving the
imaging techniques are important directions for future research.
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